BioCentury
ARTICLE | Clinical News

INNO-206: Phase IIb started

January 2, 2012 8:00 AM UTC

CytRx began an open-label, international Phase IIb trial to compare 350 mg/m 2 IV INNO-206 given once each 21-day cycle for up to 8 cycles vs. doxorubicin in 105 patients with metastatic, locally adva...